Number of the records: 1
Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study
SYS 0176162 LBL 00000naa--2200000-a-4500 005 20250607173806.9 008 211021s2021----xo-----e------------eng-- 040 $a BA006 $b slo 041 0-
$a eng $b eng 044 $a xo $c SK 245 10
$a Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study / $c Feng-E Jiang ... [et al.] 300 $b ilustr., obr., tab. 504 $a Bibliogr. odkazy 504 $a Res. angl. 650 12
$7 sllk_us_auth*d015179 $a nádory kolorektálne $x farmakoterapia $2 mesh 650 12
$7 sllk_us_auth*d004359 $a farmakoterapia kombinovaná $x metódy $2 mesh 650 22
$7 sllk_us_auth*d064420 $a účinky liekov vedľajšie a nežiaduce reakcie liekov $2 mesh 653 2-
$a nádory kolorektálne metastatatické 653 2-
$a kombinácia regorafenib a camrelizumab 653 2-
$a kombinácia frukvintinib a camrelizumab 653 2-
$a vyhodnotenie súboru pacientov 700 1-
$7 sllk_us_auth*0054612 $a Jiang, Feng-E $4 aut 773 0-
$7 nnas $w sllk_us_cat*0175762 $t Neoplasma $f Cancer Research Institute of the Slovak Academy of Sciences $x 0028-2685 $d Bratislava : AEPress, 2021 $g Vol. 68, no. 4 (2021), s. 861-866
Number of the records: 1